An Economic Model To Estimate The Public Health Impact and Cost-Effectiveness of Vaccination of Seniors with Fluzone High Dose Influenza Vaccine in Australia

Abstract

S65impact on patient quality of life due to flu-like symptoms, fatigue, and other adverse events. Sofosbuvir (SOF) is a recently approved potent NS5B-inhibitor that is welltolerated with high efficacy regardless of genotype (GT), treatment experience, or cirrhosis status. This study evaluated the health outcomes of treating CHC patients with SOF+ribavirin (R), PR, or no treatment (NT) in China. METHODS: A Markov model simulated long-term outcomes for a cohort of 10,000 CHC non-cirrhotic (NC; 36.4%) and cirrhotic (CC; 63.6%) patients with an average age of 46 over a lifetime horizon. The model assumed 61.6% of patients were GT1b; 24.2%, GT2; 8.1%, GT3; and, 6.1% GT6. CC patients accounted for 15.2% of GT1-2/6 and 21.3% for GT3. Model inputs were extrapolated from clinical trials, published literature, or expert opinion (Chinese-specific where possible). RESULTS: Across all genotypes, SOF+R led to the highest sustained virologic (SVR) rates

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

“… rVE as used in base-case analyses of HD-TIV/HD-QIV compared with TIV/QIV or aTIV/aQIV [ 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 ]. Note: no value indicates that a comparison was not evaluated.…”

“…The rVE estimate of 24.2% for HD-TIV/HD-QIV versus TIV/QIV for LCI cases, based on results from the FIM12 RCT [50], was consistently used in CEA comparing HD-TIV/HD-QIV versus TIV/QIV, and used in CEA that indirectly compared the rVE of HD-TIV/HD-QIV versus aTIV/aQIV (Tables 2B and 3B; Figure 2). [65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81]. Note: no value indicates that a comparison was not evaluated.…”

“…Figure 2. rVE as used in base-case analyses of HD-TIV/HD-QIV compared with TIV/QIV or aTIV/aQIV[65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81]. Note: no value indicates that a comparison was not evaluated.…”